Document Detail

Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.
MedLine Citation:
PMID:  21332248     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The most specific indicator of a drug-induced liver injury signal in a clinical trial database is believed to be the occurrence of subjects experiencing drug-associated elevations in both serum ALT and serum total bilirubin (TB) without a significant elevation in serum alkaline phosphatase (ALP). eDISH (evaluation of Drug-Induced Serious Hepatotoxicity) is a recently described tool that organizes liver laboratory data by graphically displaying peak serum ALT and TB levels for each subject, and can also provide direct links to the pertinent clinical and laboratory data for each subject.
OBJECTIVE: To illustrate the usefulness of the eDISH approach in the presentation of liver safety data by using phase III clinical trial data for rivaroxaban.
METHODS: Four randomized, active-controlled studies were conducted worldwide in subjects undergoing elective hip or knee replacement surgery to compare the efficacy and safety of the anticoagulant rivaroxaban, an oral, direct Factor Xa inhibitor, with the low-molecular-weight heparin, enoxaparin. Liver laboratory assessments, including ALT, AST, TB and ALP, were performed frequently during the studies. Data were incorporated into eDISH and linked data for selected subjects were analysed.
RESULTS: In the pooled analysis of the four studies, a total of 12 262 subjects (6131 rivaroxaban, 6131 enoxaparin) received at least one dose of study drug and had at least one central and/or local laboratory assessment during the study. A total of 143 (2.33%) rivaroxaban subjects and 223 (3.64%) enoxaparin subjects experienced a peak ALT >3 × upper limit of normal (ULN) but did not experience an elevation of TB >2 × ULN; these subjects are displayed in the right lower quadrant of the eDISH plot, termed the 'Temple's Corollary quadrant'. There were ten rivaroxaban and ten enoxaparin subjects with a peak ALT >3 × ULN and a peak TB >2 × ULN; these subjects were displayed in the right upper quadrant of the eDISH plot, termed the 'Hy's Law quadrant'. eDISH allowed efficient examination of the relevant data for each of these subjects.
CONCLUSIONS: The eDISH approach is an efficient and effective way to organize and examine large liver safety databases for randomized controlled clinical trials. It greatly facilitates a systematic and transparent examination of the relevant liver safety laboratory data. We believe eDISH should become a standard approach for assessing and studying liver safety issues in clinical trials.
Paul B Watkins; Mehul Desai; Scott D Berkowitz; Gary Peters; Yves Horsmans; Dominique Larrey; Willis Maddrey
Related Documents :
9769018 - Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delive...
24044638 - Effect of p-glycoprotein on the rat intestinal permeability and metabolism of the bddcs...
23187888 - Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovud...
21446568 - Preparation, characterization, cytotoxicity and drug release behavior of liposome-envel...
11274898 - Present and future in vitro approaches for drug metabolism.
10126028 - Modeling physicians' prescribing decisions for patients with panic disorder.
Publication Detail:
Type:  Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Drug safety     Volume:  34     ISSN:  0114-5916     ISO Abbreviation:  Drug Saf     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-02-21     Completed Date:  2011-06-08     Revised Date:  2014-11-17    
Medline Journal Info:
Nlm Unique ID:  9002928     Medline TA:  Drug Saf     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  243-52     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adverse Drug Reaction Reporting Systems
Alanine Transaminase / blood
Alkaline Phosphatase / blood
Arthroplasty, Replacement, Hip / methods
Arthroplasty, Replacement, Knee / methods
Bilirubin / blood
Double-Blind Method
Drug-Induced Liver Injury / epidemiology,  etiology*,  physiopathology
Enoxaparin / adverse effects*,  therapeutic use
Fibrinolytic Agents / adverse effects*,  therapeutic use
Liver Function Tests
Middle Aged
Morpholines / adverse effects*,  therapeutic use
Severity of Illness Index
Thiophenes / adverse effects*,  therapeutic use
Reg. No./Substance:
0/Enoxaparin; 0/Fibrinolytic Agents; 0/Morpholines; 0/Thiophenes; 0/rivaroxaban; EC Transaminase; EC Phosphatase; RFM9X3LJ49/Bilirubin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A computerized adverse drug event alerting system using clinical rules: a retrospective and prospect...
Next Document:  Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase.